Ecromeximab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | GD3 ganglioside |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Molar mass | 145255 g/mol |
  (what is this?) (verify) | |
Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of melanoma.[1][2][3]
The drug was developed by Kyowa Hakko Kogyo Co., Ltd. As of December 2015 development had been discontinued.[4]
